Abstract
Hyaloglide® is a hyaluronan-based gel based on a novel auto-crosslinked technology designed to reduce postsurgical adhesions. Its efficacy was assessed in a multicentred randomized controlled trial comparing the results of flexor tenolysis in zone 2 following failed flexor tendon repairs. In the control group a standard release was performed. In the treated group, Hyaloglide® was applied into the flexor sheath and around the site of tenolysis. Forty-five patients, 19 controls and 26 treated with Hyaloglide®, were enrolled in 13 centres. All the patients were evaluated at 30, 60, 90 and 180 days after surgery by testing Total Active Motion, Quick-DASH questionnaire and number of working days lost after surgery. Patients in the Hyaloglide® group had a statistically better recovery of finger motion at all time intervals and returned earlier to work and daily activities. The use of Hyaloglide® did not appear to increase the complication rate.
| Original language | English |
|---|---|
| Pages (from-to) | 130-138 |
| Number of pages | 9 |
| Journal | Journal of Hand Surgery: European Volume |
| Volume | 35 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2010 |
Fingerprint
ASJC Scopus subject areas
- Surgery
- Medicine(all)
Cite this
Efficiency of hyaloglide ® in the prevention of the recurrence of adhesions after tenolysis of flexor tendons in zone II : A randomized, controlled, multicentre clinical trial. / Riccio, M.; Battiston, B.; Pajardi, G.; Corradi, M.; Passaretti, U.; Atzei, A.; Altissimi, M.; Vaienti, L.; Catalano, F.; Del Bene, M.; Fasolo, P.; Ceruso, M.; Luchetti, R.; Landi, A.
In: Journal of Hand Surgery: European Volume, Vol. 35, No. 2, 02.2010, p. 130-138.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficiency of hyaloglide ® in the prevention of the recurrence of adhesions after tenolysis of flexor tendons in zone II
T2 - A randomized, controlled, multicentre clinical trial
AU - Riccio, M.
AU - Battiston, B.
AU - Pajardi, G.
AU - Corradi, M.
AU - Passaretti, U.
AU - Atzei, A.
AU - Altissimi, M.
AU - Vaienti, L.
AU - Catalano, F.
AU - Del Bene, M.
AU - Fasolo, P.
AU - Ceruso, M.
AU - Luchetti, R.
AU - Landi, A.
PY - 2010/2
Y1 - 2010/2
N2 - Hyaloglide® is a hyaluronan-based gel based on a novel auto-crosslinked technology designed to reduce postsurgical adhesions. Its efficacy was assessed in a multicentred randomized controlled trial comparing the results of flexor tenolysis in zone 2 following failed flexor tendon repairs. In the control group a standard release was performed. In the treated group, Hyaloglide® was applied into the flexor sheath and around the site of tenolysis. Forty-five patients, 19 controls and 26 treated with Hyaloglide®, were enrolled in 13 centres. All the patients were evaluated at 30, 60, 90 and 180 days after surgery by testing Total Active Motion, Quick-DASH questionnaire and number of working days lost after surgery. Patients in the Hyaloglide® group had a statistically better recovery of finger motion at all time intervals and returned earlier to work and daily activities. The use of Hyaloglide® did not appear to increase the complication rate.
AB - Hyaloglide® is a hyaluronan-based gel based on a novel auto-crosslinked technology designed to reduce postsurgical adhesions. Its efficacy was assessed in a multicentred randomized controlled trial comparing the results of flexor tenolysis in zone 2 following failed flexor tendon repairs. In the control group a standard release was performed. In the treated group, Hyaloglide® was applied into the flexor sheath and around the site of tenolysis. Forty-five patients, 19 controls and 26 treated with Hyaloglide®, were enrolled in 13 centres. All the patients were evaluated at 30, 60, 90 and 180 days after surgery by testing Total Active Motion, Quick-DASH questionnaire and number of working days lost after surgery. Patients in the Hyaloglide® group had a statistically better recovery of finger motion at all time intervals and returned earlier to work and daily activities. The use of Hyaloglide® did not appear to increase the complication rate.
UR - http://www.scopus.com/inward/record.url?scp=76649116868&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76649116868&partnerID=8YFLogxK
U2 - 10.1177/1753193409342044
DO - 10.1177/1753193409342044
M3 - Article
C2 - 19710086
AN - SCOPUS:76649116868
VL - 35
SP - 130
EP - 138
JO - Hand
JF - Hand
SN - 1753-1934
IS - 2
ER -